imiquimod has been researched along with Mesothelioma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Broomfield, S; Cleaver, AL; Connor, T; Currie, AJ; Fahmi Alatas, M; Fisher, SA; Khong, A; Lake, RA; Lesterhuis, WJ; Robinson, BW; Wylie, BC | 1 |
| Broomfield, SA; Currie, AJ; Mahendran, S; Prosser, AC; Robinson, BW; Smyth, MJ; Tovey, MG; van der Most, RG | 1 |
2 other study(ies) available for imiquimod and Mesothelioma
| Article | Year |
|---|---|
The efficacy of tumor debulking surgery is improved by adjuvant immunotherapy using imiquimod and anti-CD40.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibodies, Monoclonal; CD40 Antigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytoreduction Surgical Procedures; Drug Administration Schedule; Female; Imiquimod; Immunotherapy; Membrane Glycoproteins; Mesothelioma; Mice; Mice, Inbred BALB C; Neoplasms, Experimental; Toll-Like Receptor 7; Treatment Outcome | 2014 |
Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy.
Topics: Adjuvants, Immunologic; Aminoquinolines; Animals; Antibodies, Monoclonal; CD40 Antigens; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Cytotoxicity, Immunologic; Drug Therapy, Combination; Female; Imiquimod; Interferon Type I; Interferon-gamma; Killer Cells, Natural; Ligands; Membrane Glycoproteins; Mesothelioma; Mice; Mice, Inbred BALB C; Mice, Knockout; Mice, Nude; Mice, Transgenic; Toll-Like Receptor 7 | 2009 |